HRT and Low Libido: What to Know

When people ask about hormone replacement for low libido, they usually want one clear answer — and the honest version is more nuanced. Hormones can play a real role in sexual desire, but desire is also shaped by mood, medications, thyroid function, sleep, relationships, and pain during sex. In the US there is no FDA-approved testosterone product for women, and the two medications that are FDA-approved for low desire are not hormones at all. This article explains what the evidence actually shows, who the approved options are for, and what to rule out first — as education, not medical advice.

What is HSDD, and is low desire the same thing?

Low desire and HSDD are not identical. Low desire is common; the disorder requires that the low desire causes marked distress. In the PRESIDE survey of 31,581 US women (Shifren 2008), low desire overall (with or without distress) was reported by roughly 39% (38.7%), but distressing low desire consistent with HSDD was lower and varied by age — about 8.9% at ages 18–44, 12.3% at 45–64, and 7.4% at 65 and older. That distinction matters: distress is part of the diagnosis, and it is what most treatment decisions hinge on.

HSDD is specifically acquired (a change from your own baseline) and generalized (not limited to one partner or situation). If desire has always been low, or only drops in one specific context, the evaluation — and the options — can look different.

What should be ruled out before reaching for a hormone?

Several common, reversible factors can blunt desire, and addressing them sometimes resolves the problem without adding a hormone.

• Thyroid disease. Hypothyroidism is linked to female sexual dysfunction, including low desire. A 2024 meta-analysis estimated female sexual dysfunction in about 41.8% of women with hypothyroidism, and restoring normal thyroid function tends to improve it.
• Antidepressants. SSRIs and SNRIs commonly reduce libido and sexual function; sexual side effects are frequently reported early in treatment, though estimates vary widely across studies. One 2026 meta-analysis of SSRIs in depressed adults found increased orgasmic dysfunction (RR 3.28) and lower satisfaction (RR 1.21), with a non-significant trend toward lower desire (RR 1.40). Those figures describe depressed adults on these medications — not the general population.
• Painful sex (GSM). After menopause, falling estrogen can cause genitourinary syndrome of menopause (vaginal dryness, thinning, painful intercourse). Relieving pain can secondarily improve desire (more on this below).
• Mood, stress, sleep, and relationship factors, which influence desire independently of any hormone.

If you suspect a hormonal pattern, our overview of the signs you may need hormone replacement therapy can help frame a conversation with a clinician.

Does testosterone help low libido in women?

For postmenopausal women specifically, testosterone is the one hormone with a recognized, evidence-based role in HSDD — but the framing is narrow. The 2019 Global Consensus from the Endocrine Society and 10 partner societies concluded that the only evidence-based indication for female testosterone is postmenopausal HSDD, with no support for any other use, and that blood levels should stay within the range normal for healthy young women.

Critically, the US has no FDA-approved testosterone product for women. The 2021 ISSWSH clinical practice guideline notes that, absent a female product, clinicians sometimes prescribe an approved male formulation off-label at roughly one-tenth of a typical male dose, with monitoring — while compounded testosterone and pellet/implant formulations are not recommended by that guideline. Testosterone is also a DEA Schedule III controlled substance requiring a prescription and ongoing monitoring.

On safety labeling, the FDA made class-wide testosterone changes on February 28, 2025: it removed the cardiovascular boxed warning after the TRAVERSE trial — which studied 5,246 hypogonadal men ages 45–80 at high cardiovascular risk — found testosterone non-inferior to placebo for major adverse cardiac events, and added a class-wide warning that testosterone can raise blood pressure. TRAVERSE was a male trial; its results should not be read as female data. For broader context on dosing and monitoring in men, see our TRT dosage guide.

What about estrogen and vaginal dryness?

Estrogen is not a stand-alone libido treatment, but it treats a problem that often masquerades as low desire: painful sex from genitourinary syndrome of menopause (GSM). A clinical review notes that low-dose vaginal estrogen is a mainstay for GSM, with vaginal DHEA and ospemifene also FDA-approved for moderate-to-severe symptoms; for mild symptoms, non-hormonal lubricants and moisturizers are reasonable first steps. Because comfortable sex can rekindle interest, relieving pain may improve desire secondarily — even though estrogen itself is not prescribed primarily to raise libido.

Which medications are FDA-approved for low desire?

Two FDA-approved options target acquired, generalized HSDD directly — and neither is a hormone. Neither is approved for men or for sexual performance.

Feature	Vyleesi (bremelanotide)	Addyi (flibanserin)
Approved	2019	2015 (expanded Dec 15, 2025)
Type	Melanocortin receptor agonist; on-demand injection	Daily oral pill
Approved population	Premenopausal women, acquired generalized HSDD	Women under 65 (now includes postmenopausal under 65)
Key cautions	Nausea ~40%; flushing ~20%; stop at 8 weeks if no benefit	Boxed warning: alcohol can cause severe hypotension/syncope; CYP3A4 inhibitors contraindicated; contraindicated in any hepatic impairment

Bremelanotide (Vyleesi) is FDA-approved for premenopausal women with acquired generalized HSDD; the mechanism behind its effect on desire is not fully understood. In the RECONNECT phase 3 program (about 1,247–1,267 premenopausal women, mean age ~39), on-demand 1.75 mg injections over 24 weeks produced modest but statistically significant gains — per the pooled RECONNECT phase 3 publication (Kingsberg 2019), roughly +0.35 on the FSFI desire domain and about −0.33 on a distress measure versus placebo, with around 25% versus 17% classified as desire responders. The most common adverse reaction is nausea, around 40%; per the FDA/DailyMed label, about 13% required anti-emetic medication for it, with flushing, injection-site reactions, and headache also reported; the label advises stopping after 8 weeks if there is no benefit. Bremelanotide is the same molecule discussed in our PT-141 material — note that Revive’s PT-141 is a compounded, prescription-only product that is not FDA-approved, and the FDA has not evaluated it for safety, quality, or efficacy; it is not the FDA-approved branded Vyleesi.

Flibanserin (Addyi) is a daily pill FDA-approved for acquired generalized HSDD; per its DailyMed label, it is indicated for women under 65 (the December 15, 2025 expansion added postmenopausal women under 65). It carries a boxed warning that alcohol can cause severe low blood pressure and fainting, is contraindicated with CYP3A4 inhibitors, and is contraindicated in any degree of liver impairment. Like Vyleesi, it is not for men or for enhancing performance.

How do these options compare at a glance?

None of these is a guaranteed fix. The honest summary: average benefits are modest and individual results vary, so options are weighed against side effects, contraindications, and your specific situation with a clinician.

• Off-label testosterone — evidence-based only for postmenopausal HSDD; no FDA-approved female product; Schedule III; monitored.
• Vyleesi — FDA-approved, premenopausal HSDD; on-demand; nausea is common.
• Addyi — FDA-approved, women under 65; daily; alcohol/liver/CYP3A4 cautions.
• Vaginal estrogen / DHEA / ospemifene — for GSM and painful sex, which can secondarily affect desire.

Frequently asked questions

Is there an FDA-approved testosterone for women?

No. In the US there is no FDA-approved testosterone product for women. The only evidence-based indication is postmenopausal HSDD, and any use involves an approved male formulation prescribed off-label at roughly one-tenth of a typical male dose, with monitoring, per the 2021 ISSWSH guideline. That guideline does not recommend compounded testosterone or pellets.

Are Vyleesi and Addyi the same as testosterone?

No. Neither is a hormone. Vyleesi (bremelanotide) is a melanocortin receptor agonist given as an on-demand injection, and Addyi (flibanserin) is a daily pill acting on brain neurotransmitters. Both are FDA-approved for acquired, generalized HSDD — not for men or for performance.

How well does bremelanotide (Vyleesi) work?

Modestly, on average. In the RECONNECT phase 3 trials of premenopausal women with HSDD, it produced small but statistically significant improvements in desire and distress versus placebo, with about 25% versus 17% classified as responders in the RECONNECT phase 3 trials (Kingsberg 2019). It is not a guarantee, and results vary by individual.

Can low thyroid or antidepressants cause low libido?

Yes, both can. A 2024 meta-analysis found female sexual dysfunction in about 41.8% of women with hypothyroidism, and SSRIs and SNRIs commonly cause sexual side effects, including reduced desire, satisfaction, and orgasmic function in studies of depressed adults. These are different populations and different measures — they should not be combined. Because both are often reversible, clinicians typically evaluate them before adding a hormone.

Does estrogen treat low libido?

Not directly. Estrogen treats genitourinary syndrome of menopause — dryness and painful sex — and relieving pain can secondarily improve desire. It is not prescribed as a stand-alone libido treatment.

Do I need to feel distressed for this to be a treatable condition?

For an HSDD diagnosis, yes. Low desire alone is common; the disorder specifically requires that the low desire causes marked personal distress. That is why an evaluation looks at the whole picture rather than a single lab value.